-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
A project of Guangxiang Pharmaceutical has been selected as a provincial pilot project for innovative development of the industrial internet.
Category:
Time：2023-01-07
Recently, the Hebei Provincial Department of Industry and Information Technology issued a notice on the second batch of 2022 Industrial Internet Innovation and Development Pilot Projects. The high-end intelligent manufacturing upgrade project for active pharmaceutical ingredients undertaken by Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group, has been selected as a provincial pilot project for industrial internet innovation and development.
Recently, the Hebei Provincial Department of Industry and Information Technology issued a notice on the second batch of 2022 Industrial Internet Innovation and Development Pilot Projects. The high-end intelligent manufacturing upgrade project for active pharmaceutical ingredients undertaken by Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group, has been selected as a provincial Industrial Internet Innovation and Development Pilot Project.
It is reported that, in order to implement the Provincial Government’s “Implementation Opinions on Promoting the Deep Integration of the Internet and Advanced Manufacturing and Accelerating the Development of the Industrial Internet,” the Provincial Department of Industry and Information Technology, in accordance with the “2022 Hebei Province Industrial Internet Innovation and Development Key Project Application Guidelines” and the “Notice on Organizing the Application for the Second Batch of 2022 Industrial Internet Innovation and Development Pilot Projects,” has, after undergoing procedures including enterprise applications, municipal bureau review and recommendation, expert evaluation, on-site acceptance, provincial department deliberation, and online public announcement, designated a total of 50 projects as the second batch of 2022 Industrial Internet Innovation and Development Pilot Projects.
Guangxiang Pharmaceutical serves as a key pillar in Shijiazhuang Four Pharmaceutical Group’s “One Body, Two Wings” strategic development. It places great emphasis on leveraging internet information technology to promote the comprehensive and deep integration of IT with production systems, information systems, and all links in the industrial chain and value chain. This approach accelerates the digital transformation of active pharmaceutical ingredient (API) manufacturing and continuously drives the upgrading of manufacturing capabilities toward networking and intelligentization.
Over the past two years, Guangxiang Pharmaceutical has continuously upgraded its key production equipment toward automation and intelligence, leveraging its expertise in specialty API manufacturing. The company has successively acquired over a thousand units of energy-efficient, digital production equipment—including automated instruments and meters, distributed control systems, programmable logic controllers, monitoring systems, and auxiliary facilities—enabling seamless interconnection, unified management, and centralized control of numerous CNC devices, as well as real-time monitoring of production dynamics. As a result, both production capacity and efficiency have significantly improved. At the same time, by deploying an information-based management platform, the company has solidified its standardized safety production system, achieving greater transparency in safety management and substantially enhancing its levels of production manufacturing and safety management, thereby powerfully propelling its high-end API manufacturing into a new stage of intelligent development.
The head of Guangxiang Pharmaceutical stated that the next step will be to continuously refine and enhance an intelligent, green, safe, and reliable smart manufacturing system that is intensive, efficient, and data-driven. We are committed to building Digital Guangxiang—a digitally driven, intelligently integrated platform—into one of the model scenarios for active pharmaceutical ingredient (API) production in China’s modernization drive.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license